<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153305</url>
  </required_header>
  <id_info>
    <org_study_id>ERNEST - FROM/O1- 2019</org_study_id>
    <nct_id>NCT04153305</nct_id>
  </id_info>
  <brief_title>European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study</brief_title>
  <acronym>ERNEST</acronym>
  <official_title>European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Fondazione per la Ricerca Ospedale di Bergamo (FROM) decided to propose and promote the
      completion of ERNEST registry: the aim of the project is to obtain up-to-date estimates of
      clinical outcome of these patients in primary and secondary Myelofibrosis that have been
      included in the 'original' ERNEST study. The last was conducted between 2012 and beginning of
      2015 including 1292 patients with Myelofibrosis, but it was interrupted in 2015 because of
      bankruptcy of the previous sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow-up of patients already been registered in the ERNEST registry resulting alive and/or
      in active surveillance at November 2014 (Blood 2014 124:1849) will be updated retrospectively
      until December 2018. Data collection will be centralized at Fondazione per la Ricerca
      Ospedale di Bergamo (FROM), and performed by a web-based and Electronic Data Capture (EDC)
      system through ad hoc electronic case report forms (e-CRFs). The e-CRFs system will be
      pre-filled with pre-existing data collected from cases already entered in the registry.
      Information on therapies received and outcome events occurred (in term of death, evolution to
      acute leukemia, secondary cancer and cardiovascular complications) until December 2018 will
      be recorded by authorized participating investigators.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death</measure>
    <time_frame>18 years</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with evolution to acute leukemia (AL)</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of AL from diagnosis to last observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with secondary tumor (ST)</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of ST from diagnosis to last observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cardiovascular (CV) complications</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of events from diagnosis to last observation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">578</enrollment>
  <condition>Myelofibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 years old or more, with diagnosis of Primary Myelofibrosis (PMF),
        Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia
        Myelofibrosis (PET-MF) performed according WHO 2001 or WHO 2008, between 2001 and 2012.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous registration in the ERNEST registry (2012 - 2014)

          -  diagnosis of MF performed between January 2001 and 2012 December

          -  Signed informed consent to continue participation in the registry

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziano Barbui, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione per la Ricerca Ospedale di Bergamo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arianna Masciulli, PhD</last_name>
    <phone>0352678926</phone>
    <email>amasciulli@fondazionefrom.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arianna Ghirardi, PhD</last_name>
    <phone>0352678913</phone>
    <email>aghirardi@fondazionefrom.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Paoli, PhD</last_name>
      <phone>0557947688</phone>
      <email>chiara.paoli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro M Vannucchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Delaini</last_name>
      <email>oro@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessia Comino</last_name>
      <phone>0382503084</phone>
      <email>a.comino@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Elisa Rumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese</name>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessia Ingrassia</last_name>
      <phone>0332278761</phone>
      <email>alessia.ingrassia.dm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Passamonti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domenica Caramazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nic de Barcelona</name>
      <address>
        <city>Barcellona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALBERTO ALVAREZ LARRAN</last_name>
      <email>aalvar@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>ALBERTO ALVAREZ LARRAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center is Hematology Section, Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 53</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjorn Andreasson</last_name>
      <email>bjorn.andreasson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Bjorn Andreasson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helna Petterson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>survival</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>second cancer</keyword>
  <keyword>cardiovascular complication</keyword>
  <keyword>update</keyword>
  <keyword>disease management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

